Literature DB >> 17060968

Thrombotic thrombocytopenic purpura: survival by "giving a dam".

Joel L Moake1.   

Abstract

A teenager died suddenly in 1923 of systemic microvascular thrombosis. Dr. Eli Moschcowitz attributed the "hitherto undescribed disease" (now "thrombotic thrombocytopenic purpura," or "TTP") to "some powerful poison" with "both agglutinative and hemolytic properties." In 1982, TTP was found to be a defect in the "processing" of unusually large (UL) von Willebrand factor (VWF) multimers. By 1998, the cause of TTP was known to be either familial absence or acquired inhibition (by autoantibody) of plasma VWF-cleaving metalloprotease. This enzyme, the 13th member of a disintegrin and metalloprotease family with thrombospondin domains (ADAMTS-13), circulates in normal plasma waiting to cleave the long strings of ULVWF multimers emerging from stimulated endothelial cells. Uncleaved ULVWF multimers in TTP induce platelet adhesion and aggregation in the rapidly flowing blood of microvessels. Episodes of TTP are treated by "giving A DAM" (TS-13, that is) contained in normal plasma, either by infusion alone or in combination with plasmapheresis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 17060968      PMCID: PMC2263770     

Source DB:  PubMed          Journal:  Trans Am Clin Climatol Assoc        ISSN: 0065-7778


  65 in total

1.  Treatment of thrombotic thrombocytopenic purpura with plasma.

Authors:  J J Byrnes; M Khurana
Journal:  N Engl J Med       Date:  1977-12-22       Impact factor: 91.245

2.  The CUB domain. A widespread module in developmentally regulated proteins.

Authors:  P Bork; G Beckmann
Journal:  J Mol Biol       Date:  1993-05-20       Impact factor: 5.469

3.  Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group.

Authors:  G A Rock; K H Shumak; N A Buskard; V S Blanchette; J G Kelton; R C Nair; R A Spasoff
Journal:  N Engl J Med       Date:  1991-08-08       Impact factor: 91.245

4.  Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients.

Authors:  W R Bell; H G Braine; P M Ness; T S Kickler
Journal:  N Engl J Med       Date:  1991-08-08       Impact factor: 91.245

Review 5.  Thrombotic microangiopathies associated with drugs and bone marrow transplantation.

Authors:  J L Moake; J J Byrnes
Journal:  Hematol Oncol Clin North Am       Date:  1996-04       Impact factor: 3.722

6.  Shear stress enhances the proteolysis of von Willebrand factor in normal plasma.

Authors:  H M Tsai; I I Sussman; R L Nagel
Journal:  Blood       Date:  1994-04-15       Impact factor: 22.113

7.  Real-time analysis of shear-dependent thrombus formation and its blockade by inhibitors of von Willebrand factor binding to platelets.

Authors:  B R Alevriadou; J L Moake; N A Turner; Z M Ruggeri; B J Folie; M D Phillips; A B Schreiber; M E Hrinda; L V McIntire
Journal:  Blood       Date:  1993-03-01       Impact factor: 22.113

8.  Solvent/detergent-treated plasma suppresses shear-induced platelet aggregation and prevents episodes of thrombotic thrombocytopenic purpura.

Authors:  J Moake; M Chintagumpala; N Turner; P McPherson; L Nolasco; C Steuber; P Santiago-Borrero; M Horowitz; J Pehta
Journal:  Blood       Date:  1994-07-15       Impact factor: 22.113

Review 9.  Thrombotic microangiopathies in the 1980s: clinical features, response to treatment, and the impact of the human immunodeficiency virus epidemic.

Authors:  C E Thompson; L E Damon; C A Ries; C A Linker
Journal:  Blood       Date:  1992-10-15       Impact factor: 22.113

10.  Quinine-induced immune thrombocytopenia associated with hemolytic uremic syndrome: a new clinical entity.

Authors:  J L Gottschall; W Elliot; E Lianos; J G McFarland; K Wolfmeyer; R H Aster
Journal:  Blood       Date:  1991-01-15       Impact factor: 22.113

View more
  3 in total

Review 1.  Historical perspective and future directions in platelet research.

Authors:  B S Coller
Journal:  J Thromb Haemost       Date:  2011-07       Impact factor: 5.824

2.  High-density lipoprotein modulates thrombosis by preventing von Willebrand factor self-association and subsequent platelet adhesion.

Authors:  Dominic W Chung; Junmei Chen; Minhua Ling; Xiaoyun Fu; Teri Blevins; Scott Parsons; Jennie Le; Jeff Harris; Thomas R Martin; Barbara A Konkle; Ying Zheng; José A López
Journal:  Blood       Date:  2015-11-09       Impact factor: 22.113

Review 3.  Inflammation, von Willebrand factor, and ADAMTS13.

Authors:  Junmei Chen; Dominic W Chung
Journal:  Blood       Date:  2018-06-04       Impact factor: 25.476

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.